Navigation Links
Number of Children, Teens Being Treated for Mental Disorders is on Rise

According to a report published in the issue of Archives of General Psychiatry, it is disturbing to note that the number of patients, under the age of 20, being treated with antipsychotic medications, is rising steadily//.

Antipsychotics are medications used to treat mental disorders, such as schizophrenia and mania that may involve loss of contact with reality. Several studies have indicated that prescriptions for these medications have been increasing among children and adolescents, raising concerns among professionals and the public. However, no national data have previously been available, according to background information in the article. Most prescriptions given to children and adolescents are for second-generation antipsychotics, which are not approved by the U.S. Food and Drug Administration for pediatric patients.

Mark Olfson, M.D., M.P.H., College of Physicians and Surgeons, Columbia University, New York, and colleagues analyzed data from a national survey of office-based physicians conducted yearly by federal researchers. In addition to recording whether the child or adolescent patient received a prescription for antipsychotics, the physician or a staff member also logged the patient’s age, sex and race or ethnicity; the length of the visit; the physician’s specialty and whether the patient received psychotherapy.

The number of outpatient health care visits during which patients between the ages of 0 and 20 years received antipsychotic medications increased six-fold between 1993 and 2002, from a yearly average of 201,000 between 1993 and 1995 to 1,224,000 in 2002. For every 100,000 individuals younger than age 21 in the United States, 274.7 such office visits took place each year from 1993 to 1995, compared with 1,341 each year from 2000 to 2002. Overall, 9.2 percent of mental health visits and 18.3 percent of visits to psychiatrists included antipsychotic treatment. Diagnoses among the patients receiving these medica tions included disruptive behavior disorder (37.8 percent), mood disorders (31.8 percent), pervasive developmental disorders or mental retardation (17.3 percent) and psychotic disorders (14.2 percent). Male and white youth were most likely to receive such treatments.

The availability of new antipsychotics with fewer side effects in adults may have contributed to the increase. In addition, fewer inpatient care options are available for children with mental illnesses, requiring physicians to treat more seriously ill children in an outpatient setting. These severely ill patients are more likely to require powerful medications like antipsychotics. Although these medications may be safe and effective for some mental disorders in pediatric patients, further research is needed to confirm this and provide detailed information about benefits and risks, the authors write.

'In recent years, second-generation antipsychotic medications have become common in the office-based mental health treatment of young people,' they conclude. 'These medications are used to treat children and adolescents with different mental disorders. Results of clinical trials provide a limited base of support for the short-term safety and efficacy of some second-generation antipsychotic medications for psychosis and disruptive behavior disorders. In light of the widespread and growing use of these medications, there is a pressing need to increase and extend the experimental evaluation of these medications in children and adolescents.'

(Source: Newswise)
'"/>




Related medicine news :

1. Reducing Number Of Cigarettes Not Enough
2. An Increase In Number Of Lung Cancer Deaths in Women
3. Estimates For Number Of HIV/AIDS Deaths In India Still Not Available
4. Number Of Babies Born Prematurely Nears Historic Half Million Mark In US
5. Smokers Are Prone To Number Of Psychiatric Disorders
6. AIDS Numbers Continue To Rise : WHO
7. WBSACS Says Number Of AIDS Cases On The Rise
8. Number Of Dementia Cases To Rise Drastically
9. Increase in the Number of Cases of Animal Diseases in New South Wales.
10. Record Number of Countries Contributed to UNFPA in 2005
11. Australia Witnesses A Fall In the Number of Organ Donors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: